Michael Carter Net Worth & Insider Trades

Michael Carter - Director, Oncternal Therapeutics, Inc

As of June 30, 2023

What is Michael Carter's Net Worth?

The current estimated net worth of Oncternal Therapeutics, Inc's Director, Michael Carter, is estimated to be about $64.15K . Michael Carter owns about 71,947 units of Oncternal Therapeutics, Inc common stock. In the last 4 years at Oncternal Therapeutics, Inc, Michael Carter has sold an estimated value of $0 worth.

What is Michael Carter's Past Insider Trading?

Michael Carter's largest purchase order was 71,429 units , worth over $150K on September 2, 2020. In total, Michael Carter has made about 6 transactions over 4 years of their time at Oncternal Therapeutics, Inc. Michael Carter usually trades in June, with the busiest year in 2020.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

MICHAEL CARTER

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is Michael Carter's' Mailing Address?

  • Mailing address is C/o Cancer Vax Corp 2110 Rutherford Road Carlsbad CA 92008 CA

What are Oncternal Therapeutics, Inc's Past Insider Trades?

Oncternal Therapeutics, Inc's most recent insider trade came on June 14, 2023 by Gunnar Kaufmann who bought 28,000 units worth $9.82K . In the last 3 years, insiders at Oncternal Therapeutics, Inc have sold an estimated value of $115.54K and bought an estimated value of $2.97M worth of shares. Insider trading is most common in June, with the busiest year in 2023 and 2022. The most active traders at the company are James Breitmeyer, Chief Executive Officer,  Richard Vincent, Chief Financial Officer,  and Chase C Leavitt, General Counsel/Secretary .

Oncternal Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...